益方生物 (688382)
InventisBio Co., Ltd.
K-Line Chart
No K-line data available
Company NameInventisBio (Shanghai) Co., Ltd.
Listing Date2022-07-25
Issue Price18.12RMB
Registered Capital57834.849110k RMB
Legal RepresentativeYaolin Wang
Registered AddressRoom 210, No. 4, Lane 67, Libing Road, China (Shanghai) Pilot Free Trade Zone
IndustryChemical Pharmaceuticals
Main BusinessIt is an innovative drug R&D enterprise based in China with a global vision, focusing on major disease areas such as oncology and metabolic diseases.
Company ProfileInventisBio (Shanghai) Co., Ltd. is a clinical-stage drug R&D company. The company is committed to developing first-in-class and best-in-class innovative drugs with proprietary intellectual property rights targeting major diseases such as oncology and metabolic disorders. InventisBio was co-founded by Dr. Yaolin Wang and several other returnee Ph.D.s. The core team has an average of over 18 years of experience in leading drug R&D projects and team management at large multinational pharmaceutical companies. InventisBio is a drug discovery company based in China with a global perspective. Its philosophy is to uphold the craftsmanship spirit, develop high-quality, China-created, globally-oriented (In China, for the Globe) innovative drugs, provide patients with safe and effective targeted and immunotherapies, address a significant number of unmet medical needs, and benefit patients.
Stock Details
1. Key Indicators
- Total Shares(W): 57834.85
- Circulating A-Shares(W): 41763.33
- Earnings Per Share(RMB): -0.31
- Net Assets Per Share(RMB): 2.88
- Operating Revenue(W RMB): 3089.35
- Total Profit(W RMB): -18124.60
- **Net Profit Attributable to Parent(W RMB) **: -18138.52
- Net Profit Growth Rate(%): 40.59
- Weighted Return on Equity(%): -10.42
- Operating Cash Flow Per Share(RMB): -0.28
- Undistributed Profit Per Share(RMB): -4.71
- Capital Reserve Per Share(RMB): 6.62
2. Main Business
The main business covers:
- Research and development of innovative drugs
- Production of innovative drugs
- Sales of innovative drugs
3. Company Basic Information
- Company Name: InventisBio (Shanghai) Co., Ltd.
- Listing Date: 2022-07-25
- Industry: Pharmaceutical Manufacturing
- Address: Room 210, No. 4, Lane 67, Libing Road, China (Shanghai) Pilot Free Trade Zone
- Website: https://www.inventisbio.com/
- Company Profile: InventisBio (Shanghai) Co., Ltd. was established in 2020 through the overall change of Inventis Limited. It is a biotechnology company focused on the research and development of innovative drugs. The company's unified social credit code is 913101150609007219.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 1621.61 | 3.88 |
| 2 | ABA-Bio (Hong Kong) Limited | General Legal Person | 1112.00 | 2.66 |
| 3 | China Universal Innovative Medicine Theme Hybrid Securities Investment Fund Class A | Fund | 1031.11 | 2.47 |
| 4 | LAV Apex Hong Kong Limited | General Legal Person | 897.92 | 2.15 |
| 5 | OAP III (HK) Limited | General Legal Person | 837.81 | 2.01 |
| 6 | China Europe Healthcare Hybrid Securities Investment Fund Class A | Fund | 814.77 | 1.95 |
| 7 | Yongying Pharmaceutical Innovation Smart Selection Hybrid Initiation Securities Investment Fund Class A | Fund | 792.19 | 1.90 |
| 8 | Shanghai Yixi Enterprise Management Center (Limited Partnership) | General Legal Person | 682.12 | 1.63 |
| 9 | UBS AG | QFII | 629.97 | 1.51 |
| 10 | Ping An Healthcare Hybrid Securities Investment Fund Class A | Fund | 627.49 | 1.50 |
5. Concept Sectors
- Innovative Drugs
- Margin Trading & Securities Lending
- QFII Heavy Positions
- Consecutive Losses
- Pension Funds
- QFII New Entries
- Fund Reduction
- Science and Technology Innovation Board Growth Layer
- Science and Technology Innovation Board Biotech
- Science and Technology Innovation Board 200
- SSE 580
Remarks
- Data update date: 2025-09-30
- Data source: Public market information